Agilent Technologies, Inc.
A Healthcare Diagnostics & Research
Agilent Technologies, Inc.’s revenue for fiscal 2025 (year ended October 2025) was $6.9 billion, up 6.73% from fiscal 2024. In the quarter to July 2026, revenue grew 8.06%, EPS grew 8.47%, free cash flow grew 69.5% and total debt rose 8.81%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow A
Agilent Technologies, Inc. (A) Revenue
Agilent Technologies, Inc.'s revenue for fiscal 2025 was $6.9B, up 6.73% from $6.5B in fiscal 2024. Over the twelve months to 31 July 2026 it was $7.4B. Over the past ten years it has ranged from $4.0B (fiscal 2015) to $6.9B (fiscal 2025) — the current reading is the highest in ten years. Agilent Technologies, Inc. ranks 7th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $6.9B | 6.73% |
| FY2024 | $6.5B | (4.73%) |
| FY2023 | $6.8B | (0.22%) |
| FY2022 | $6.8B | 8.37% |
| FY2021 | $6.3B | 18.36% |
| FY2020 | $5.3B | 3.41% |
| FY2019 | $5.2B | 5.07% |
| FY2018 | $4.9B | 9.88% |
| FY2017 | $4.5B | 6.43% |
| FY2016 | $4.2B | 4.06% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jul 2026 | $1.9B | 2.34% |
| Apr 2026 | $1.8B | 2.06% |
| Jan 2026 | $1.8B | (3.39%) |
| Oct 2025 | $1.9B | 7.08% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| IQV IQVIA Holdings Inc. compare | $17.0B |
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| A Agilent Technologies, Inc. | $7.4B |
| WAT Waters Corporation compare | $4.6B |
| IDXX IDEXX Laboratories, Inc. compare | $4.6B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| NTRA Natera, Inc. compare | $2.7B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on A
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement